Artivion, Inc. (AORT)
$
42.81
-0.14 (-0.33%)
Key metrics
Financial statements
Free cash flow per share
-0.2501
Market cap
2 Billion
Price to sales ratio
4.9870
Debt to equity
0.0209
Current ratio
4.7821
Income quality
1.1896
Average inventory
84.3 Million
ROE
-0.0554
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Artivion Inc. manufactures, processes, and distributes a wide array of medical devices and implantable human tissues across the globe. The company reported an income before tax of -$7,514,000.00 showcasing its pre-tax profitability. Its operational efficiency is further highlighted by the EBITDA ratio of 0.13. The total costs and expenses for the company are $349,663,000.00 reflecting its overall spending in various operations and developments. In addition to its core business, Artivion earned an interest income of $1,467,000.00 showcasing its financial investments. The diluted EPS is -$0.32 accounting for potential share dilution, indicating the company's performance impact on shareholders. Among its diverse product offerings are BioGlue, PhotoFix, various stent grafts for vascular treatments, and synthetic vascular grafts, catering to the needs of cardiac, vascular, and thoracic surgeons, thereby enhancing patient care and surgical outcomes. The stock is affordable at $31.68 suitable for budget-conscious investors looking to enter the market. However, the stock has a low average trading volume of 407,974.00 indicating lower market activity which may affect liquidity. With a market capitalization of $2,019,934,197.00 the company is classified as a small-cap player, reflecting its position in the industry. Artivion is a key player in the Medical - Devices industry, contributing significantly to the overall market landscape and showcasing a commitment to innovation. Furthermore, it belongs to the Healthcare sector, driving innovation and growth while addressing critical healthcare needs. The combination of an affordable stock price and a strategic focus on manufacturing advanced medical technologies positions Artivion as an intriguing option for investors interested in impactful healthcare advancements.
Is Artivion, Inc. (AORT) a good investment?
Investing in Artivion, Inc. (AORT) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bullish outlook. Always conduct your own research before investing.
What is Artivion, Inc. (AORT)'s stock forecast?
Analysts predict Artivion, Inc. stock to fluctuate between $21.97 (low) and $43.97 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Artivion, Inc.'s market capitalization?
As of 2025-08-15, Artivion, Inc.'s market cap is $2,019,934,197, based on 47,183,700 outstanding shares.
How does Artivion, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Artivion, Inc. has a Lower Market-Cap, indicating a difference in performance.
Does Artivion, Inc. pay dividends?
Artivion, Inc. pays dividends. The current dividend yield is 1.15%, with a payout of $0.03 per share.
How can I buy Artivion, Inc. (AORT) stock?
To buy Artivion, Inc. (AORT) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for AORT. Place an order (Market, Limit, etc.).
What is the best time to invest in Artivion, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Artivion, Inc. stock ever split?
Artivion, Inc.'s last stock split was 3:2 on 2000-12-28.
How did Artivion, Inc. perform in the last earnings report?
Revenue: $388,537,000 | EPS: -$0.32 | Growth: -57.33%.
Where can I find Artivion, Inc.'s investor relations reports?
Visit https://artivion.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Artivion, Inc.?
You can explore historical data from here
What is the all-time high and low for Artivion, Inc. stock?
All-time high: $43.97 (2025-08-13) | All-time low: $9.64 (2022-10-12).
What are the key trends affecting Artivion, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
Artivion, Inc. (NYSE:AORT ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Lance A. Berry - Executive VP of Finance & CFO Pat MacKin - Corporate Participant Conference Call Participants Daniel Walker Stauder - Citizens JMP Securities, LLC, Research Division Destiny Alexandra Hance Buch - Ladenburg Thalmann & Co. Inc., Research Division John Glenn McAulay - Stifel, Nicolaus & Company, Incorporated, Research Division William John Plovanic - Canaccord Genuity Corp., Research Division Dorothy Morgan - Gilmartin Group LLC Operator Good day, ladies and gentlemen, and welcome to the Artivion Second Quarter 2025 Earnings Call.
globenewswire.com
NEWTOWN, Pa., July 13, 2025 (GLOBE NEWSWIRE) -- The law firm of Edelson Lechtzin LLP is investigating data privacy claims regarding an incident at Artivion, Inc. (“Artivion”).
prnewswire.com
ATLANTA , June 3, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming investors conferences. Artivion's management team will present at the upcoming Truist Securities MedTech Conference on Tuesday, June 17, 2025, at the InterContinental Boston Hotel.
prnewswire.com
ATLANTA , May 28, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the closing of transactions related to previously announced, privately negotiated exchange agreements with certain holders (the "Holders") of its 4.250% Convertible Senior Notes due 2025 (the "Notes"). The closing transactions included the closing of an additional, privately negotiated agreement with a separate holder.
seekingalpha.com
Artivion, Inc. (NYSE:AORT ) Q1 2025 Earnings Conference Call May 5, 2025 4:30 PM ET Company Participants Dorothy Morgan - Gilmartin Group LLC Pat Mackin - Chief Executive Officer Lance Berry - Chief Financial Officer Conference Call Participants John McAulay - Stifel Frank Takkinen - Lake Street Capital Markets Suraj Kalia - Oppenheimer & Company Mike Matson - Needham & Company Daniel Stauter - Citizens Jeffrey Cohen - Ladenburg Thalmann Operator Greetings. Welcome to Artivion's First Quarter 2025 Financial Conference Call.
zacks.com
Artivion (AORT) came out with quarterly earnings of $0.06 per share, missing the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.06 per share a year ago.
prnewswire.com
ATLANTA , April 21, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that first quarter 2025 financial results will be released on Monday, May 5, 2025, after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m.
seekingalpha.com
Artivion, Inc. (NYSE:AORT ) Q4 2024 Earnings Conference Call February 24, 2025 4:30 PM ET Company Participants Dorothy Morgan - Gilmartin Group LLC Pat Mackin - Chief Executive Officer Lance Berry - Chief Financial Officer Conference Call Participants Rick Wise - Stifel Frank Takkinen - Lake Street Capital Markets Suraj Kalia - Oppenheimer & Company Mike Matson - Needham & Company Daniel Stauter - Citizens Jeffrey Cohen - Ladenburg Thalmann Operator Greetings, and welcome to the Artivion Fourth Quarter and Year End 2024 Financial Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.
zacks.com
Artivion (AORT) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of $0.12. This compares to earnings of $0.11 per share a year ago.
See all news
